Treatment of hidradenitis suppurativa

Abstract

Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.

What is claimed is: 
     
         1 . A method of treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-IL-1a antibody effective to treat a symptom of hidradenitis suppurativa in the subject. 
     
     
         2 . The method of  claim 1 , wherein the anti-IL-1a antibody is a monoclonal antibody. 
     
     
         3 . The method of  claim 2 , wherein the monoclonal antibody is an IgG1. 
     
     
         4 . The method of  claim 3 , wherein the monoclonal antibody is MABp1. 
     
     
         5 . The method of  claim 1 , wherein the subject's HiSCR score is improved after administration of the pharmaceutical composition. 
     
     
         6 . The method of  claim 1 , wherein the median size of the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition. 
     
     
         7 . The method of  claim 1 , wherein the subject's pain associated with the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition. 
     
     
         8 . The method of  claim 1 , wherein the subject's time to new hidradenitis suppurativa lesions is increased after administration of the pharmaceutical composition. 
     
     
         9 . The method of  claim 1 , wherein the hidradenitis suppurativa in the human subject has failed to resolve after treatment with tumor necrosis factor alpha inhibitors. 
     
     
         10 . The method of  claim 1 , further comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti- S. aureus  antibody. 
     
     
         11 . The method of  claim 10 , wherein the anti- S. aureus  antibody comprises a Fab region paratope that specifically binds to  S. aureus  protein A (SpA) and an Fc region that does not specifically bind SpA.